Get the Stockscreener App
0.6845
9.57%
0.0598
After Hours:
.69
0.0055
+0.80%
Curis Inc stock is traded at $0.6845, with a volume of 3.49M.
It is up +9.57% in the last 24 hours and down -27.95% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$0.6247
Open:
$0.6124
24h Volume:
3.49M
Relative Volume:
8.74
Market Cap:
$27.37M
Revenue:
$9.44M
Net Income/Loss:
$-7.58M
P/E Ratio:
-0.5733
EPS:
-1.194
Net Cash Flow:
$-27.20M
1W Performance:
+25.39%
1M Performance:
-27.95%
6M Performance:
-54.97%
1Y Performance:
-46.94%
1-Day Range:
$0.597
$0.79
1-Week Range:
$0.4902
$0.79
52-Week Range:
$0.4902
$3.13
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
0.6845 | 24.97M | 9.44M | -7.58M | -27.20M | -1.194 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Curis Inc (CRIS) Stock Price & 30 Year Financial Data - GuruFocus
Sell Signal: Whats the MACD signal for Curis Inc2026 Setups & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Form PRE 14AOther preliminary proxy statements - ADVFN
Curis (NASDAQ: CRIS) holds virtual meeting May 19; board seeks more authorized shares - Stock Titan
CRIS Should I Buy - Intellectia AI
Curis targets full enrollment in PCNSL registrational study within 12–18 months while advancing CLL proof-of-concept - MSN
Nantahala shows 4.22M stake in Curis (NASDAQ: CRIS) — 9.99% - Stock Titan
Nantahala Capital (CRIS) reports 2.94M shares, 6.98% ownership (exercisable stakes included) - Stock Titan
Curis Inc. (CUS0.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Curis, Inc. (CRIS) stock price, news, quote and history - Yahoo Finance Singapore
CRIS Stock Price, Quote & Chart | CURIS INC (NASDAQ:CRIS) - ChartMill
Curis director Kaitin buys $5487 in shares By Investing.com - Investing.com South Africa
Curis director Kaitin buys $5487 in shares - Investing.com UK
Director at Curis (NASDAQ: CRIS) makes open-market share buy - Stock Titan
Market Review: What are analysts price targets for Curis IncQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Curis prices private placement of $80.8M - MSN
Aug Big Picture: Is Curis Inc exposed to political riskMarket Sentiment Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Stonepine Group (NASDAQ: CRIS) reports 4.03M shares, 9.9% stake - Stock Titan
Curis, Inc. 2025 Annual Report: Emavusertib Development, Regulatory Pathways, and Key Business Risks - Minichart
Curis (NASDAQ: CRIS) warns on going concern amid emavusertib push - Stock Titan
CURIS (CRIS) CDO Jonathan Zung converts Series B preferred into 66,667 common shares - Stock Titan
Curis (CRIS) CMO converts Series B preferred stock to common shares - Stock Titan
CURIS INC (CRIS) CFO converts Series B preferred into 66,666 common shares - Stock Titan
Curis (CRIS) CEO converts Series B preferred stock into common shares - Stock Titan
Curis Inc (CRIS) director converts Series B preferred into 26,667 common shares - Stock Titan
Curis, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
[EFFECT] CURIS INC SEC Filing - Stock Titan
Curis Earnings Call: Clinical Momentum Amid Revenue Void - TipRanks
Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M - AlphaStreet
Curis (CRIS) Q4 2025 Earnings Call Transcript - AOL.com
Curis Inc stock faces renewed scrutiny amid pipeline delays and cash burn concerns - AD HOC NEWS
Curis, Inc. (NASDAQ:CRIS) Q4 2025 Earnings Call Transcript - Insider Monkey
CRIS: HC Wainwright & Co. Reiterates Buy Rating with $17.00 Pric - GuruFocus
Curis reports Q4 results, secures up to $80.8M financing By Investing.com - Investing.com India
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ... By GuruFocus - Investing.com Canada
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit and Strategic Focus - gurufocus.com
Curis Q4 2025 Earnings Call Transcript - MarketBeat
Curis, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Curis Inc. Q4 2025 sees turnaround with net income - Investing.com India
Curis Inc’s NHL Prioritization, PCNSL Timeline Shifts, and CLL Data Delays Clash in 2025 Q4 Earnings Call - Bitget
Curis Reports Progress on Lymphoma Study & Expands CLL Research with EmavusertibNews and Statistics - IndexBox
Curis (CRIS) Q4 2025 Financial Results Conference Call Transcript - Bitget
Earnings call transcript: Curis Inc. Q4 2025 sees turnaround with net income By Investing.com - Investing.com South Africa
Curis Provides Fourth Quarter 2025 Business Update - GuruFocus
Curis: Fourth Quarter Earnings Overview - Bitget
Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Curis (CRIS) Q4 2025 Earnings Call Transcript - The Motley Fool
Curis (CRIS) Reports Lower Than Expected Q4 Revenue - gurufocus.com
Curis Q4 & Full-Year 2025 Financial Results: $19.4M Net Income, $1.1M RevenueNews and Statistics - IndexBox
Curis: Overview of Fourth Quarter Financial Results - Bitget
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):